[Factors related to the outcome of patients with chronic severe hepatitis B and effectiveness of antivirus therapy].
OBJECTIVE
To investigate the factors related to the outcome of patients with chronic severe hepatitis B and effectiveness of antivirus therapy.


METHODS
The effects of the factors including age, prothrombin activity (PTA), serum HBeAg, Anti-HBe, HBV-DNA load, with or without complication, antivirus therapy and so on, on outcome of 330 patients with chronic severe hepatitis B were analyzed in this retrospective study.


RESULTS
The mortality of patients with chronic severe hepatitis B was significantly higher among patients at higher age, with lower PTA, and with more complications. The mortality of patients with HBV-DNA more than 1x10(5) copies/ml (52.3 percent) was higher than that of patients whose HBV-DNA was less than 1x10(5) copies/ml (32.9 percent). There was no correlation between serum HBeAg or anti-HBe and the mortality. The mortality of patients with HBV-DNA higher than 1x10(5) copies/ml (30.38 percent) who were treated with lamivudine in 2005 was lower than that of patients whose HBV-DNA was less than 1x10(5) copies/ml (54.64 percent) who were not treated with any antiviral therapy in 2001.


CONCLUSIONS
The higher serum virus load is the key factors of the mortality in addition to the other factors such as older age, lower PTA, more complication in the patients with chronic severe hepatitis B. The usage of antivirus therapy may be associated with lower mortality.
Wu
Yun-zhong
YZ
Department of Infectious Diseases, Beijing Ditan Hospital, Beijing 100011, China.
Zhao
Feng-lin
FL
Zhang
Chun-ze
CZ
Li
Ming-hui
MH
Xie
Yao
Y
D000328:Adult; D000367:Age Factors; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011516:Prothrombin / Q000378:metabolism; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D019259:Lamivudine; D011516:Prothrombin